← All trials
NCT06796699
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 7, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Feb 29, 2028
- First posted
- Jan 28, 2025
- Last posted
- Mar 28, 2025
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Genhouse Bio Co., Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.